Liver Metastases Studies
TheraSphere for the Treatment of Liver Metastases
Gregory A. Wiseman, M.D.
Secretary phone: 507-284-4399
Teresa Mettler, RN
An Open Label Trial of TheraSphere in Patients with Liver Metastases from Primary Colorectal Cancer, Neuroendocrine or Non-Colorectal/Non-Neuroendocrine Cancer
- To evaluate Progression Free Survival (PFS) following TheraSphere treatment, as determined by CT/MRI images according to RECIST criteria.
- To evaluate the safety of TheraSphere treatment at doses of 120 ± 10% Gy in patients with metastatic disease to the liver.